Merestinib
Merestinib is a small molecule inhibitor with potential antineoplastic activity. It is primarily researched for its ability to inhibit multiple receptor tyrosine kinases (RTKs), which are known to play crucial roles in various forms of cancer. Merestinib targets the MET (mesenchymal-epithelial transition) receptor, AXL, and MKNK1/2 among others, disrupting cancer cell signaling and proliferation.
Mechanism of Action
Merestinib works by inhibiting the activity of several receptor tyrosine kinases, including MET, AXL, and MKNK1/2. The MET proto-oncogene is particularly significant in the progression of many cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and renal cell carcinoma. By blocking the MET signaling pathway, merestinib can inhibit tumor growth and metastasis. AXL receptor tyrosine kinase is involved in tumor cell survival, growth, migration, and angiogenesis. Inhibition of AXL by merestinib can lead to reduced tumor aggressiveness and increased sensitivity to other anticancer agents.
Clinical Trials
Merestinib has been evaluated in various phases of clinical trials for its efficacy and safety in treating different types of cancers. One of the notable studies includes its investigation in combination with other therapeutic agents for the treatment of NSCLC and other solid tumors. The outcomes of these studies are crucial for understanding the potential therapeutic window of merestinib in oncology.
Pharmacokinetics
The pharmacokinetic profile of merestinib includes its absorption, distribution, metabolism, and excretion characteristics in the human body. Understanding these parameters is essential for optimizing dosing regimens to achieve maximum therapeutic efficacy while minimizing adverse effects.
Adverse Effects
As with many anticancer agents, merestinib can cause a range of adverse effects. These may include, but are not limited to, fatigue, nausea, vomiting, and hematologic abnormalities such as anemia and thrombocytopenia. Monitoring and management of these side effects are critical components of patient care during treatment with merestinib.
Future Directions
Research continues to explore the full potential of merestinib in cancer therapy, including its use in combination with other treatments. The identification of biomarkers that predict response to merestinib could also enhance its application in precision medicine, allowing for more targeted and effective cancer treatment strategies.
Chemotherapy | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
This Chemotherapy related article is a stub.
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD